Bengaluru-based startup 4baseCare has secured ₹128 crore in its latest Series B funding round. This fresh capital will help scale the company’s genomic testing network. Specifically, the startup aims to make precision oncology more inclusive across emerging markets. Consequently, they plan to expand their services across India, the Middle East, Southeast Asia, and Latin America. Additionally, the funding will help upgrade OncoTwin, their proprietary artificial intelligence platform.
Advancing Precision Oncology Globally
Currently, most genomic datasets heavily represent Caucasian populations. Therefore, drug discovery and clinical trials often miss critical insights for diverse cohorts. To address this gap, 4baseCare develops solutions for under-represented populations. Furthermore, the company has established functional laboratories in India, Nepal, Dubai, and the Philippines. Over the next 12 to 18 months, they plan to expand into eight to ten more countries. Consequently, local patients will gain better access to advanced diagnostic tools.
Decentralizing Genomic Testing in India
In India, the company is actively decentralizing its diagnostic infrastructure. Previously, hospitals had to ship all patient samples directly to Bengaluru. However, the startup now partners with local healthcare leaders like Max Healthcare and AIIMS Jammu. As a result, they can establish dedicated in-hospital genomics labs. Indeed, this decentralized model significantly improves diagnostic turnaround times. Moreover, it fosters stronger research collaborations between clinicians.
The Role of OncoTwin AI Platform
The startup’s OncoTwin platform uses multimodal datasets to assist oncologists. Specifically, it integrates genomic, pathology, radiology, and clinical information. By doing so, the system creates “digital twins” of cancer patients. Consequently, doctors can review real-world evidence and compare treatment journeys of similar patients. This technology does not directly recommend treatments. Instead, it provides doctors with evidence-based insights to optimize patient outcomes. Practitioners looking to expand their expertise in this field can benefit from a certification course in clinical oncology.
Frequently Asked Questions
Q1: What is OncoTwin?
OncoTwin is an AI-powered clinical decision support platform. Specifically, it creates digital twins of cancer patients by analyzing genomic and clinical datasets. Consequently, doctors can compare treatment pathways and outcomes of similar cases.
Q2: Why is decentralizing genomic testing important?
Previously, hospitals shipped all clinical samples to central labs in major cities. However, setting up in-hospital genomic labs brings advanced technology closer to patients. Consequently, this model improves diagnostic turnaround times and enhances local clinical research.
References
- Infosys-backed 4baseCare raises ₹128 cr, plans to take its cancer testingplatform global – ETHealthworld
- Infosys-backed precision oncology startup 4baseCare raises Rs 128 Cr – Entrackr
- 4baseCare raises Rs 90 Cr in Series B round to scale AI powered precision oncology platform – BioSpectrum India
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.